The United States has achieved a significant public health milestone: youth tobacco use has fallen to historic lows. This success is the result of years of prevention efforts, stricter age restrictions, public education, and a societal consensus that nicotine products should not be used by minors. According to the FDA's analysis of the 2025 National Youth Tobacco Survey, current use of tobacco products, combustible tobacco products, and e-cigarettes declined between 2022 and 2025. Nicotine pouch use among youth remained low and stable, with 1.7% reporting current use in 2025, down from 1.8% in 2024. These data contradict the perception that youth tobacco use is on the rise and underscore the effectiveness of existing measures.
However, the public health challenge is not over. While youth use is down, adult smoking remains the leading cause of preventable death in the United States, according to the CDC. Millions of adults continue to smoke despite decades of warnings and restrictions. For those adults who cannot or will not quit completely, access to accurate information about scientifically substantiated smoke-free alternatives is crucial. This is where the FDA's recent action on ZYN nicotine pouches becomes significant. After a rigorous scientific review, the FDA issued modified risk orders for 20 ZYN nicotine pouch products, allowing them to be marketed with the claim: "using ZYN instead of cigarettes puts adults at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." The FDA did not declare these products safe, nor did it encourage non-users to start using nicotine. Instead, it authorized a claim that helps adult smokers understand the relative risks of switching completely to these pouches.
This distinction is vital. Nicotine products are addictive and not risk-free. They are not intended as nicotine replacement therapies like patches or gum, and they are not a substitute for quitting tobacco and nicotine altogether. However, science-based policy should recognize the meaningful differences in risk between combustible cigarettes and smoke-free alternatives for adults who switch completely. The FDA's authorization reflects a balanced approach that does not undermine youth prevention efforts. In fact, the latest youth tobacco data demonstrate that these two goals are not mutually exclusive. Historically low youth tobacco use can coexist with a marketplace that includes FDA-authorized smoke-free alternatives for adults.
PMI U.S., the company behind ZYN, has been explicit that these products are for current nicotine consumers aged 21 and older, not for youth, non-users, or those trying to quit nicotine entirely. Their responsible marketing practices include advertising featuring only individuals aged 35 or older, independent online age verification for website visitors, and restrictions on social media platforms that allow age controls. They do not pay influencers or engage in product placement in movies or TV shows. These steps are part of a broader 10-point approach to underage prevention, which includes age-gated websites, monitoring of underage-use data, retail support programs, and support for FDA compliance checks.
No single entity can tackle this alone. The right framework is practical and evidence-based: keep nicotine products away from anyone under 21, enforce minimum age laws, address illicit products, maintain clear product standards, and require responsible marketing. The United States has made extraordinary progress in reducing youth tobacco use, and that progress must be protected. The next step is to apply the same seriousness to helping adults who still smoke. A mature tobacco policy should be able to do both: prevent young people from starting and help adults who continue to smoke move to better alternatives. These goals are not in opposition; they belong together.
